A Therapeutic Platelet Transfusion Strategy without Routine Prophylactic Transfusion Is Feasible and Safe and Reduces Platelet Transfusion Numbers Significantly: Preliminary Analysis of a Randomized Study in Patients after High Dose Chemotherapy and Autol

Hannes Wandt, Knut Wendelin, Kerstin Schaefer-Eckart, Markus Thalheimer, Mario Stephan Schubert, Roland Conradi, Rainer Schwerdtfeger, Lothar Leimer, Martin Kaufmann, Gottfried Dölken, Anne Friederike Klenner, Markus Schaich, and Gerhard Ehninger

Author address: 

1 Medical Department 5, Klinikum Nuernberg Nord, Nuernberg, Germany, 2 Medical Department 5, University Heidelberg, Germany, 3 DKD Wiesbaden, Germany, 4 Robert Bosch Krankenhaus, Stuttgart, Germany, 5 Hematology/Oncology, University Greifswald, Germa


We performed a multicenter randomized trial comparing the traditional prophylactic platelet transfusion strategy -arm P- (trigger: morning platelet count 10/nL) with an experimental therapeutic transfusion strategy -arm T- where patients (pts) received platelet transfusions only if they experienced clinically relevant bleeding (more than petechias or minimal mucosal bleeding). The morning platelet count was no trigger in arm T for transfusion as well as fever per se. Fever was no additional risk factor for bleeding in thrombocytopenic pts treated with our therapeutic transfusion strategy as published recently. (Wandt, H et al. Bone Marrow Transplant 2006; 37:387392[Medline]) For safety reasons prophylactic transfusion was recommended in arm T, however, for pts with invasive aspergillosis, sepsis syndrome and unexpected headache. Randomisation was stratified according to age (

abstract No: 


Full conference title: 

50th American Society of Haematologists Annual Meeting
    • ASH 50th (2008)